GF CART 01
Alternative Names: GF-CART01Latest Information Update: 23 Apr 2025
At a glance
- Originator GenomeFrontier
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 13 Apr 2025 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in Taiwan (Parenteral) (NCT06703892)
- 02 Dec 2024 GenomeFrontier Therapeutics plans a phase I trial for B-Cell Hematological Malignancies (Second-line therapy or greater) in Taiwan (Parenteral) in March 2025 (NCT06703892)
- 20 Oct 2023 GF CART 01 is available for licensing as of 20 Oct 2023. https://genomefrontier.com/partnership/